(±)16(17)-EpDPA
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)16(17)-EpDPA is the DHA homolog of (±)14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of DHA. The EDHF activity of (±)16(17)-EpDPA has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a mouse inflammation model.[4]
Catalog Number | T37235 |
Alternative Name(s) | (±)16,17-EpDPE , (±)16,17 EDP , (±)16,17-epoxy Docosapentaenoic Acid , (±)16,17-epoxy DPA , (±)16(17)-EpDPA |
Molecular Formula | C22H32O3 |
CAS# | 155073-46-4 |
SMILES | CC\C=C/C[C@H]1O[C@H]1C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O |
Size | 1 mg |
Supplier Page | https://www.targetmol.com/compound/(±)16(17)-epdpa |
Additional Information | https://www.targetmol.com/datasheet/T37235 |